Borah BJ, Laughlin-Tommaso SK, Myers ER, Yao X, Stewart EA. Association between patient characteristics and treatment procedure among uterine leiomyoma patients.
Obstet Gynecol 2015;126.
The authors provided this information as a supplement to their article.
© Copyright 2015 American College of Obstetricians and Gynecologists. Page 1 of 5
Appendix 1. Current Procedural Terminology (CPT) Codes for Identifying Study Cohorts
Treatment Category CPT-4 Codes
Uterine Artery Embolization (UAE)# 36247, 37204, 52250, 37210 and require UF dx on claim for each of the codes Endometrial ablation 56356, 58353, 58563
Hysterectomy
Total abdominal 58150, 58152, 58200,58953, 58954, 58956
Vaginal 58260,58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294
Laparoscopic or robotic 58550, 58552, 58553, 58554, 58541, 58542, 58543, 58544, 58570, 58571, 58572, 58573, 58578#
Subtotal 58180
Radical# 58210, 58548 and require UF diagnosis on claim for each of the codes
Myomectomy
Abdominal 58140, 58146
Vaginal 58145
Laparoscopy 58545,58546, 58551
Borah BJ, Laughlin-Tommaso SK, Myers ER, Yao X, Stewart EA. Association between patient characteristics and treatment procedure among uterine leiomyoma patients.
Obstet Gynecol 2015;126.
The authors provided this information as a supplement to their article.
© Copyright 2015 American College of Obstetricians and Gynecologists. Page 2 of 5
Appendix 2. ICD-9 Codes for Uterine Fibroids and Related Comorbid Conditions
DESCRIPTION ICD-9-CM DIAGNOSIS CODE
Uterine fibroids 218.xx, 219.xx, 654.1x
Menstrual disorders 626.xx
Pelvic pain 625.xx
Anemias 280.xx, 285.xx
Inflammatory diseases 614.xx, 616.xx
Noninflammatory diseases 620.xx, 622.xx
Endometriosis 617.xx
Urinary problems 788.41, 788.20-788.29, 591.xx, 593.5x
Constipation or gas 564.00, 564.09, 787.3
Disorders of the uterus not elsewhere classified 621.xx
Genital prolapse 618.xx
Benign neoplasm of the uterus/ovary 220.xx
Borah BJ, Laughlin-Tommaso SK, Myers ER, Yao X, Stewart EA. Association between patient characteristics and treatment procedure among uterine leiomyoma patients.
Obstet Gynecol 2015;126.
The authors provided this information as a supplement to their article.
© Copyright 2015 American College of Obstetricians and Gynecologists. Page 3 of 5
Appendix 3. List of NSAIDS and Hormones
Group of Drugs Generic Names
NSAIDS Al Hydroxide/Mg Trisilicate/Phenylbutazone, Antipyrine/Caffeine/Sodium Salicylate, BROMFENAC SODIUM, CELECOXIB, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM, Diclofenac Sodium/Misoprostol, ETODOLAC, FENOPROFEN CALCIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, Indomethacin Sodium, KETOROLAC TROMETHAMINE, Lansoprazole/Naproxen, MECLOFENAMATE SODIUM, MEFENAMIC ACID, MELOXICAM, NABUMETONE, NAPROXEN, NAPROXEN SODIUM, Nepafenac, OXAPROZIN, Oxyphenbutazone, PHENYLBUTAZONE, PIROXICAM, ROFECOXIB, SULINDAC, TOLMETIN SODIUM, VALDECOXIB
Progestins and oral contracetives DESOGESTREL/ETHINYL ESTRADIOL, DROSPIRENONE/ETHINYL ESTRADIOL, ESTONE/PROGESTERONE, Estradiol Cypionate/Medroxyprogesterone Acetate, ESTRONE/TESTOSTERON, Ethinyl Estradiol/Ethynodiol Diacetate, ETHINYL
ESTRADIOL/FE FUM/NORETHIN, Ethinyl Estradiol/Ferrous Fum/Norethindrone Ace, Ethinyl Estradiol/Levonorgestrel, ETHINYL ESTRADIOL/NORELGESTROMIN, ETHINYL ESTRADIOL/NORETHIN ACE, Ethinyl Estradiol/Norethindrone, Ethinyl Estradiol/Norethindrone Acetate, ETHINYL ESTRADIOL/NORGESTIMATE, ETHINYL ESTRADIOL/NORGESTREL, HYDROXYPROGESTERONE CAPROATE, LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, Mestranol/Norethindrone, NORETHINDRONE, NORETHINDRONE ACETATE, NORGESTREL, PROGESTERONE GnRH-a - Gonadotrophin-releasing
hormone agonist
Abarelix/Sodium Chloride, CETRORELIX ACETATE, FOLLITROPIN BETA/GANIRELIX ACETATE, Ganirelix Acetate, GONADORELIN ACETATE, GONADORELIN HYDROCHLORIDE, GOSERELIN ACETATE, HISTRELIN ACETATE, LEUPROLIDE ACETATE, NAFARELIN ACETATE, TRIPTORELIN PAMOATE
Danazol Danazol
Note: NSAIDS: Non-steroidal anti-inflammatory drugs
Borah BJ, Laughlin-Tommaso SK, Myers ER, Yao X, Stewart EA. Association between patient characteristics and treatment procedure among uterine leiomyoma patients.
Obstet Gynecol 2015;126.
The authors provided this information as a supplement to their article.
© Copyright 2015 American College of Obstetricians and Gynecologists. Page 4 of 5
Appendix 4. Attrition for Women With Surgical Treatments for Uterine Leiomyoma Patients
N Female patients age 25-54 in Thomson Reuters Marketscan® Commercial Claims and Encounters Databases between
01/01/2003 and 12/31/2010.
25,371,009 Patients with at least one inpatient or two outpatient claims occurring 30 days apart for uterine fibroids (ICD-9-CM
diagnosis code of 218.xx, 219.xx or 654.1x) occurring on or between 01/01/2003 and 12/31/2010.
584,425
Patients with any UF procedure occurring on or between 01/01/2004 and 12/31/2009 321,640
Patients continuously enrolled with medical and pharmacy coverage 380 days prior to index date
1,2196,908 Patients continuously enrolled with medical and pharmacy coverage 352 days post index date
2126,662 Patents with one of the following FOUR study procedures (myomectomy, endometrial ablation, uterine artery
embolization or hysterectomy
96852
Myomectomy 7039
Endometrial Ablation 12169
Uterine Artery Embolization 3835
Hysterectomy 73809
1
Index Date is the date of the first surgery
2
Allow for up to a 30 day gap in enrollment
Borah BJ, Laughlin-Tommaso SK, Myers ER, Yao X, Stewart EA. Association between patient characteristics and treatment procedure among uterine leiomyoma patients.
Obstet Gynecol 2015;126.
The authors provided this information as a supplement to their article.
© Copyright 2015 American College of Obstetricians and Gynecologists. Page 5 of 5
Appendix 5. Marginal Effects of Age and Race Interactions on the Probability of Uterine-Sparing Procedure Compared With Hysterectomy
Age Group # Race Quintile
Marginal Effects
Adjusted P-Values
†[95%
Conf. Interval]
1#1 0.200 0.005 0.037 0.364
1#2 0.217 <0.001 0.149 0.285
1#3 0.354 <0.001 0.304 0.404
1#4 0.426 <0.001 0.390 0.462
1#5 0.500 <0.001 0.474 0.526
2#1 0.167 <0.001 0.114 0.221
2#2 0.199 <0.001 0.177 0.222
2#3 0.224 <0.001 0.210 0.239
2#4 0.243 <0.001 0.232 0.253
2#5 0.304 <0.001 0.294 0.315
3#1 0.138 <0.001 0.094 0.181
3#2 0.169 <0.001 0.151 0.188
3#3 0.177 <0.001 0.166 0.188
3#4 0.189 <0.001 0.180 0.197
3#5 0.218 <0.001 0.208 0.227
Note: Age group 1: 25-34; Age group 2: 35-44; Age group 3: 45-54
†Adjusted p-values are based on Bonferroni correction.
